Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

3期 已完成 NCT01994109

摘要

This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands. MYOBLOC has been shown in previous trials to safely decrease saliva production, thereby demonstrating its potential as a safe and effective treatment for troublesome sialorrhea.

Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)

4 Weeks · g/minute

Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A)

4 weeks · score on a scale

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Ed — Shionogi
• Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic L — Shionogi
• Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
• Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
• Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis — Shionogi
• Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS — Shionogi

全部试验